Please login to the form below

Not currently logged in
Email:
Password:

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

SoseiTargeting largest family of proteins in cell membranes

Recursion raises $121m for AI-led drug discovery

RecursionFunds will fuel in house pipeline and tech

AbbVie cures STING fever with Mavupharma acquisition

AbbVie RedwoodJoins host of companies pursuing novel mechanism

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Alzweb1Latest BACE inhibitor to run into trouble

ViiV builds case for switching to its two-drug HIV combinations

ViiV HealthcareTaking aim at rival Biktarvy

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

PoxelTreatment can help patients with advanced disease, companies say

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

UK gov AMRPilot much more to industry liking, but devil will be in detail

Boehringer tests speech as early warning for CNS diseases

Brain scanCompany extends foray into digital health innovation

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics